Georgia 2023-2024 Regular Session

Georgia House Bill HB857 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 LC 52 0164
22 A BILL TO BE ENTITLED
33 AN ACT
44 To amend Chapter 4 of Title 49 of the Official Code of Georgia Annotated, relating to public1
55 assistance, so as to make insulin accessible, under certain conditions, to an eligible individual2
66 who needs an affordable supply of insulin for up to one year, with the option to renew3
77 annually; to provide for a short title; to provide for definitions; to require a manufacturer of4
88 insulin to establish a patient assistance program and alternative plans for making insulin5
99 more affordable and accessible to qualifying Georgia residents; to provide for an individual6
1010 to apply directly to the manufacturer; to require a manufacturer to promptly determine7
1111 eligibility and to provide an individual with an eligibility statement; to require a pharmacy8
1212 to dispense a 90 day supply of insulin to an eligible individual through such program; to9
1313 allow the pharmacy to collect a co-payment not to exceed $75.00 for insulin dispensed10
1414 through such program; to provide for re-orders and renewals; to provide for the development11
1515 of an application form, an information sheet, and satisfaction surveys; to provide for12
1616 enforcement, penalties, and appellate procedures; to provide for reporting; to provide for13
1717 related matters; to provide for an effective date; to repeal conflicting laws; and for other14
1818 purposes.15
1919 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:16
2020 - 1 - LC 52 0164
2121 SECTION 1.17
2222 Chapter 4 of Title 49 of the Official Code of Georgia Annotated, relating to public assistance,18
2323 is amended by adding a new article to read as follows:19
2424 "Article 1020
2525 49-4-200.21
2626 This article shall be known and may be cited as the 'Continuing Insulin Safety Net Act.'22
2727 49-4-201.23
2828 As used in this article, the term:24
2929 (1) 'Alternative plan' means an alternative plan established by the manufacturer as25
3030 provided for in Code Section 49-4-202.26
3131 (2) 'Department' means the Department of Community Health.27
3232 (3) 'Eligible individual' means an individual qualified for assistance under the program28
3333 as provided for in Code Section 49-4-203.29
3434 (4) 'Insulin' means various types of insulin analogs and insulin-like medications,30
3535 regardless of activation period or whether the solution is mixed before or after31
3636 dispensation. An insulin product is exempt from the provisions of this article if the32
3737 wholesale acquisition cost of the insulin is $8.00 or less per milliliter or applicable33
3838 National Council for Prescription Drug Plan billing unit, for the entire assessment time34
3939 period, adjusted annually based on the Consumer Price Index.35
4040 (5) 'Manufacturer' means a manufacturer engaged in the production of insulin that is36
4141 self-administered on an outpatient basis. Such term shall not include a manufacturer with37
4242 an annual gross revenue of $2 million or less from insulin sales in this state.38
4343 (6) 'Pharmacy' shall have the same meaning as provided in Code Section 26-4-5.39
4444 - 2 - LC 52 0164
4545 (7) 'Program' means the patient assistance program established by each manufacturer as40
4646 provided for in Code Section 49-4-202.41
4747 (8) 'Proper identification' means any document issued by a governmental agency42
4848 containing a description of the individual, such individual's photograph, or both, and43
4949 giving such individual's date of birth, and includes, without being limited to, a passport,44
5050 military identification card, driver's license, or identification card authorized under Code45
5151 Sections 40-5-100 through 40-5-104. Proper identification shall not include a birth46
5252 certificate.47
5353 49-4-202.48
5454 (a) Each manufacturer shall make a patient assistance program that:49
5555 (1) Is made available to eligible individuals;50
5656 (2) Provides a 90 day supply of insulin at no charge to an eligible individual or pharmacy51
5757 and can be re-ordered for up to one year; and52
5858 (3) Is renewable annually if an individual still meets eligibility requirements.53
5959 (b) To ensure that insulin is affordable and accessible to Georgia residents in need of54
6060 insulin each manufacturer shall, in addition to the program, establish at least one alternative55
6161 plan, such as a cost-sharing assistance plan or a mechanism for providing an emergency56
6262 or urgent supply of insulin.57
6363 (c) Each manufacturer shall:58
6464 (1) Provide information about its program and any alternative plans to the department;59
6565 (2) Post information and a hotline for the program and any alternative plans on its60
6666 website; and61
6767 (3) Provide for dedicated personnel to promptly respond to individuals, pharmacies,62
6868 healthcare providers, and the department regarding the program and any alternative plans.63
6969 - 3 - LC 52 0164
7070 49-4-203.64
7171 (a) To be deemed eligible to participate in a manufacturer's program, an individual shall:65
7272 (1) Provide proper identification that indicates the individual is a resident of this state. 66
7373 If the individual is under the age of 18, such individual's parent or legal guardian shall67
7474 provide proper identification that indicates residency of this state;68
7575 (2) Have a family income that is equal to or less than 400 percent of the federal poverty69
7676 guidelines;70
7777 (3) Not be enrolled in medical assistance;71
7878 (4) Not be eligible to receive healthcare through a federally funded program or receive72
7979 prescription drug benefits through the Department of Veteran Affairs; provided, however,73
8080 that an individual who is enrolled in Medicare Part D is eligible for a manufacturer's74
8181 patient assistance program if such individual has spent $1,000.00 or more on prescription75
8282 drugs in the current calendar year; and76
8383 (5) Not be enrolled in prescription drug coverage through an individual or group health77
8484 plan that limits the total amount of cost-sharing for a 90 day supply of insulin, including78
8585 co-payments, deductibles, or coinsurance to $75.00 or less, regardless of the type or79
8686 amount of insulin needed.80
8787 (b) An individual shall apply directly to the manufacturer to participate in the program. 81
8888 Upon receipt of an application for the program, the manufacturer shall process the82
8989 application and determine eligibility of the individual. The manufacturer shall notify the83
9090 applicant within ten business days of receipt of the application. When additional84
9191 information is required, the manufacturer shall notify the applicant within five business85
9292 days of receipt of the application as to what additional information is required. Within86
9393 three business days of receipt of the requested additional information, the manufacturer87
9494 shall determine eligibility of the individual and shall notify the applicant of such88
9595 determination.89
9696 - 4 - LC 52 0164
9797 (c) When the individual is determined to be eligible, the manufacturer shall provide such90
9898 individual with an eligibility statement. An individual's eligibility is valid for twelve91
9999 months and is renewable upon a redetermination of eligibility.92
100100 (d) When the individual is determined to be ineligible, the manufacturer shall include in93
101101 its notification the reasons for such determination. The individual may appeal the94
102102 determination as provided for in Code Section 49-4-205.95
103103 (e) The manufacturer shall provide to any applicant deemed ineligible information about96
104104 any alternative plans available to such individual.97
105105 49-4-204.98
106106 (a) An eligible individual shall submit to a pharmacy the eligibility statement provided by99
107107 the manufacturer.100
108108 (b) Upon receipt of an individual's eligibility statement, the pharmacy shall submit an101
109109 order containing the name of the insulin product and the daily dosage amount as contained102
110110 in a valid prescription to the product's manufacturer. The pharmacy shall include with the103
111111 order to the manufacturer the pharmacy's name and shipping address, necessary contact104
112112 information, and any specific days or times when deliveries are not accepted by such105
113113 pharmacy.106
114114 (c) Upon receipt of an order and necessary information as provided for in subsection (b)107
115115 of this Code section, the manufacturer shall send to the pharmacy a 90 day supply of108
116116 insulin as ordered, unless a lesser amount is requested in the order, at no charge to the109
117117 individual or pharmacy.110
118118 (d) Except as authorized under subsection (e) of this Code section, the pharmacy shall111
119119 provide the insulin to the individual at no charge to such individual. The pharmacy shall112
120120 not provide insulin received from the manufacturer to any individual other than the113
121121 individual associated with the specific order. The pharmacy shall not seek reimbursement114
122122 for the insulin received from the manufacturer or from any third-party payer.115
123123 - 5 - LC 52 0164
124124 (e) The pharmacy may collect a co-payment from the individual to cover the pharmacy's116
125125 costs for processing and dispensing the insulin in an amount not to exceed $50.00 for each117
126126 90 day supply of insulin sent to and dispensed from the pharmacy for an order or for a118
127127 re-order.119
128128 (f) The pharmacy may submit to a manufacturer a reorder for an individual if such120
129129 individual's eligibility has not expired. Upon receipt of a reorder from a pharmacy, the121
130130 manufacturer shall send to the pharmacy an additional 90 day supply of insulin, unless a122
131131 lesser amount is requested, at no charge to the individual or the pharmacy.123
132132 (g) Notwithstanding subsection (c) of this Code section, a manufacturer may send the124
133133 insulin as ordered directly to the individual if the manufacturer provides a mail order125
134134 service option.126
135135 49-4-205.127
136136 (a) When an individual disagrees with a manufacturer's determination of ineligibility, such128
137137 individual may contact the department to request a review of such determination. Such129
138138 review shall be completed by a panel composed of three members of the department. The130
139139 individual requesting the review shall submit to the department with the request for review131
140140 all documents submitted by the individual to the manufacturer, which the department shall132
141141 provide to the panel. The panel shall render a decision within ten business days of receipt133
142142 of all the necessary documents from the individual. The decision of the panel shall be134
143143 final.135
144144 (b) If the panel determines that the individual is eligible, the manufacturer shall provide136
145145 the individual with an eligibility statement.137
146146 49-4-206.138
147147 (a) The department, in coordination with the manufacturer, shall develop an information139
148148 sheet that shall include, but shall not be limited to:140
149149 - 6 - LC 52 0164
150150 (1) A description of the program, including how to access it and information about any141
151151 alternative plans;142
152152 (2) Information on applying for medical assistance;143
153153 (3) Information on applying for a qualified health plan offered through the exchange as144
154154 defined in Code Section 33-23-201; and145
155155 (4) Information on accessing healthcare providers who participate in prescription drug146
156156 discount programs, including providers who are authorized to participate in the 340B147
157157 program under section 340B of the federal Public Health Service Act, 42 U.S.C.148
158158 Section 256b, as amended.149
159159 (b) The department shall post the information sheet provided for in subsection (a) of this150
160160 Code section on its website.151
161161 49-4-207.152
162162 (a) The department, in coordination with the manufacturer, shall develop a survey to assess153
163163 an eligible individual's satisfaction with the program and any alternative plans, including:154
164164 (1) Adequacy of information available and provided to individuals;155
165165 (2) Accessibility to insulin; and156
166166 (3) Individual's ability to access affordable insulin.157
167167 (b) The department, in coordination with the manufacturer, shall develop a survey to158
168168 assess a pharmacy's satisfaction with the program and alternative plans, including:159
169169 (1) Ease in submitting claims and insulin product orders to the manufacturers; and160
170170 (2) Timeliness of receiving insulin re-orders or renewal orders from the manufacturers.161
171171 (c) The department shall post the surveys provided for in subsections (a) and (b) of this162
172172 Code section on its website.163
173173 - 7 - LC 52 0164
174174 49-4-208.164
175175 (a) Any data collected, created, received, maintained, or disseminated by the department165
176176 pursuant to this article related to an individual seeking access to the program or any166
177177 alternative plans shall be kept confidential and shall be retained for no longer than ten167
178178 years.168
179179 (b) Each pharmacy and manufacturer shall maintain the privacy of all data received from169
180180 any individual applying for the manufacturer's program or any alternative plans and shall170
181181 be prohibited from selling, sharing, or disseminating such data received unless required to171
182182 do so under this article or when an individual has provided the manufacturer with signed172
183183 authorization.173
184184 49-4-209.174
185185 (a) Any person who by means of a false statement, failure to disclose information, or175
186186 impersonation, or by other fraudulent device, obtains, attempts to obtain, or retains for176
187187 himself, herself, or any other person any medical assistance or other benefit or payment177
188188 under this article to which such person is not entitled or in an amount greater than that to178
189189 which such person is entitled shall be guilty of a misdemeanor. If the total amount of the179
190190 value of the assistance so obtained exceeds $1,500.00, such person shall be guilty of a180
191191 felony.181
192192 (b)(1) If a manufacturer fails to comply with the provisions of this article, the department182
193193 may assess an administrative penalty of $200,000.00 per month of such noncompliance.183
194194 (2) Such penalty shall increase to $400,000.00 per month if the manufacturer continues184
195195 to be in noncompliance after six months and shall increase to $600,000.00 per month if185
196196 the manufacturer continues to be in noncompliance after one year.186
197197 (3) The penalty shall remain at $600,000.00 per month for as long as the manufacturer187
198198 continues in noncompliance.188
199199 - 8 - LC 52 0164
200200 (c) An individual or entity that is aggrieved by the action of the department pursuant to189
201201 subsections (a) or (b) of this Code section shall be entitled to a hearing conducted in190
202202 accordance with Chapter 13 of Title 50, the 'Georgia Administrative Procedure Act.'191
203203 49-4-210.192
204204 (a) By February 15, 2024, and every February 15 thereafter, each manufacturer shall report193
205205 to the department the following information for the preceding calendar year:194
206206 (1) A description of the program and any changes made to the program;195
207207 (2) The number of Georgia residents who accessed and received insulin through the196
208208 program;197
209209 (3) The total value of the insulin, determined by the wholesale acquisition cost of the198
210210 insulin, provided by the manufacturer through the program;199
211211 (4) A description of the alternative plans and any changes made to them;200
212212 (5) The number of Georgia residents who accessed and received insulin through the201
213213 alternative plans;202
214214 (6) The total value of the insulin, determined by the wholesale acquisition cost of the203
215215 insulin, provided by the manufacturer through the alternative plans;204
216216 (7) The number of individuals deemed ineligible for the program or the alternative plans205
217217 and the reasons for their ineligibility;206
218218 (8) The number of appeals and the number of eligibility statuses that were sustained or207
219219 reversed;208
220220 (9) The timeliness and adequacy of the manufacturers in responding to individuals209
221221 applying for the program or the alternative plans and pharmacies requesting insulin210
222222 through the program or the alternative plans;211
223223 (10) Any administrative penalties assessed under Code Section 49-4-209; and212
224224 (11) Any additional information deemed necessary by the department.213
225225 - 9 - LC 52 0164
226226 (b) By February 15, 2024, and every February 15 thereafter, a pharmacy that received any214
227227 eligibility statements from individuals for the program or the alternative plans shall report215
228228 to the department the following information for the preceding calendar year:216
229229 (1) The number of eligibility statements received;217
230230 (2) The amount of insulin dispensed through the program;218
231231 (3) The average and total amount of copayment collected from individuals;219
232232 (4) The timeliness and adequacy of manufacturers' responses; and220
233233 (5) Any additional information deemed necessary by the department.221
234234 (b) By March 15, 2025, and every March 15 thereafter, the department shall submit to the222
235235 General Assembly a report regarding the implementation of the program under this article. 223
236236 Such report shall include the following information for the preceding year:224
237237 (1) The data collected under subsections (a) and (b) of this Code section;225
238238 (2) The results of the satisfaction surveys provided for in Code Section 49-4-207; and226
239239 (3) Any additional information deemed necessary by the department to assess the227
240240 implementation and effectiveness of the program."228
241241 SECTION 2.229
242242 This Act shall become effective upon its approval by the Governor or upon its becoming law230
243243 without such approval.231
244244 SECTION 3.232
245245 All laws and parts of laws in conflict with this Act are repealed.233
246246 - 10 -